Literature DB >> 3574489

Short-acting novel MAO inhibitors: in vitro evidence for the reversibility of MAO inhibition by moclobemide and Ro 16-6491.

H H Keller, R Kettler, G Keller, M Da Prada.   

Abstract

The inhibition of monoamine oxidase (MAO) in rat liver and brain by the short-acting MAO-A inhibitors moclobemide (Ro 11-1163 = p-chloro-N-[2-morpholinoethyl]benzamide) and brofaremine and by the short-acting MAO-B inhibitors Ro 16-6491 (N-[2-aminoethyl]-p-chloro-benzamide) and almoxatone, administered p.o. at roughly equieffective doses 2 h before decapitation, was investigated for its reversibility under various in vitro conditions. MAO A activity in liver homogenates, inhibited by moclobemide (300 mumol/kg) to approx. 15% of control, time dependently recovered during 0.5 to 2 h of incubation at 37 degrees C, irrespective of whether the homogenates were prepared and incubated in distilled water or Krebs-Ringer buffer (KRB). Dialysis of such homogenates for 4 h in distilled water at 37 degrees C (but not at 13 degrees C) led to a complete return of the MAO activity. In liver homogenates from rats pretreated with brofaremine (30 mumol/kg), dialysis for 4 h at 37 degrees C against distilled water caused only little recovery of the MAO activity. Likewise, MAO-B inhibited by Ro 16-6491 (30 mumol/kg) to approx. 4% of control returned to almost control activity after 4 h of dialysis at 37 degrees C, while inhibition induced by almoxatone (30 mumol/kg) was little or not reversed at all. In brain homogenates prepared in, and dialysed against, distilled water or KRB at 37 degrees C (but not at 13 degrees C), MAO-A inhibited by moclobemide (100-300 mumol/kg) to approx. 15% of control, partially (KRB) or almost completely (dist. water) returned to control activity after 4 h of dialysis.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3574489     DOI: 10.1007/bf00165029

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  17 in total

1.  A SENSITIVE AND SPECIFIC ASSAY FOR THE ESTIMATION OF MONOAMINE OXIDASE.

Authors:  R J WURTMAN; J AXELROD
Journal:  Biochem Pharmacol       Date:  1963-12       Impact factor: 5.858

Review 2.  Neuronal monoamine oxidase: specific enzyme types and their rates of formation.

Authors:  N H Neff; C Goridis
Journal:  Adv Biochem Psychopharmacol       Date:  1972

3.  Removal of discrete fresh regions of the rat brain.

Authors:  D M Jacobowitz
Journal:  Brain Res       Date:  1974-11-08       Impact factor: 3.252

4.  Neurochemical effects in vitro and in vivo of the antidepressant Ro 11-1163, a specific and short-acting MAO-A inhibitor.

Authors:  M Da Prada; R Kettler; H H Keller; W E Haefely
Journal:  Mod Probl Pharmacopsychiatry       Date:  1983

5.  The pseudoirreversible inhibition of monoamine oxidase by allylamine.

Authors:  R R Rando; A Eigner
Journal:  Mol Pharmacol       Date:  1977-11       Impact factor: 4.436

6.  (+)-4-Dimethylamino-2,alpha-dimethylphenethylamine (FLA 336(+)), a selective inhibitor of the A form of monoamine oxidase in the rat brain.

Authors:  A L Ask; K Högberg; L Schmidt; H Kiessling; S B Ross
Journal:  Biochem Pharmacol       Date:  1982-04-01       Impact factor: 5.858

7.  Cardiocirculatory effects of moclobemide (Ro 11-1163), a new reversible, a short-acting MAO-inhibitor with preferential type A inhibition, in healthy volunteers and depressive patients.

Authors:  S Gasic; A Korn; H G Eichler; I Oberhummer; H G Zapotoczky
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

8.  Mechanism of inactivation of monoamine oxidase by 1-phenylcyclopropylamine.

Authors:  R B Silverman; P A Zieske
Journal:  Biochemistry       Date:  1985-04-23       Impact factor: 3.162

9.  The monoamine oxidase inhibiting properties of CGP 11305 A.

Authors:  P C Waldmeier; A E Felner; K F Tipton
Journal:  Eur J Pharmacol       Date:  1983-10-14       Impact factor: 4.432

10.  On the reversibility of reversible MAO inhibitors.

Authors:  P C Waldmeier
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-05       Impact factor: 3.000

View more
  8 in total

Review 1.  Serotonin syndrome and drug combinations: focus on MAOI and RIMA.

Authors:  S E Hilton; H Maradit; H J Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1997       Impact factor: 5.270

2.  Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers.

Authors:  M Koulu; M Scheinin; A Kaarttinen; J Kallio; K Pyykkö; J Vuorinen; R H Zimmer
Journal:  Br J Clin Pharmacol       Date:  1989-02       Impact factor: 4.335

3.  Non-adrenergic binding of [3H]atipamezole in rat kidney--regional distribution and comparison to alpha2-adrenoceptors.

Authors:  B Sjöholm; J Lähdesmäki; K Pyykkö; M Hillilä; M Scheinin
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

4.  Plasma moclobemide and metabolites: lack of correlation with clinical response and biogenic amines.

Authors:  J Fritze; G Laux; E Sofic; P Koronakis; M P Schoerlin; P Riederer; H Beckmann
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

5.  Effects of the antidepressant pirlindole and its dehydro-derivative on the activity of monoamine oxidase-A and on GABAA receptors.

Authors:  A E Medvedev; V I Shvedov; T M Chulkova; O A Fedotova; E Saederup; R F Squires
Journal:  Neurochem Res       Date:  1996-12       Impact factor: 3.996

Review 6.  Biochemistry and pharmacology of moclobemide, a prototype RIMA.

Authors:  W Haefely; W P Burkard; A M Cesura; R Kettler; H P Lorez; J R Martin; J G Richards; R Scherschlicht; M Da Prada
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

7.  Moclobemide excretion in human breast milk.

Authors:  G Pons; M P Schoerlin; Y K Tam; C Moran; J P Pfefen; C Francoual; A M Pedarriosse; J Chavinie; G Olive
Journal:  Br J Clin Pharmacol       Date:  1990-01       Impact factor: 4.335

8.  Monoamine Oxidase Inhibitors (MAOIs) in Psychiatric Practice: How to Use them Safely and Effectively.

Authors:  Samuel R Chamberlain; David S Baldwin
Journal:  CNS Drugs       Date:  2021-07-09       Impact factor: 5.749

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.